News >

Bendamustine Plus Rituximab Shows Promise as Induction Therapy in Mantle Cell Lymphoma

Caroline Seymour
Published: Thursday, Feb 20, 2020

Diego Villa, MD, MPH, a clinical associate professor in the Division of Medical Oncology, Department of Medicine, The University of British Columbia

Diego Villa, MD, MPH

The combination of bendamustine and rituximab (Rituxan; BR) was found to be an effective induction regimen in patients with mantle cell lymphoma (MCL), irrespective of transplant eligibility, according to data from a single-center, retrospective analysis presented at the 2019 ASH Annual Meeting.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication